Live feed07:00:00·2020dPRReleasevia QuantisnowDeciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal TumorByQuantisnow·Wall Street's wire, on your screen.DCPH· Deciphera Pharmaceuticals Inc.Health CareOriginal source
